Compare NWPX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWPX | ANL |
|---|---|---|
| Founded | 1966 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.9M | 731.6M |
| IPO Year | 1996 | 2022 |
| Metric | NWPX | ANL |
|---|---|---|
| Price | $118.75 | $11.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $70.00 | $20.00 |
| AVG Volume (30 Days) | 115.7K | ★ 141.8K |
| Earning Date | 04-29-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.71 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $526,003,000.00 | N/A |
| Revenue This Year | $6.98 | $36.02 |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | $110.83 | ★ N/A |
| Revenue Growth | ★ 6.79 | N/A |
| 52 Week Low | $38.46 | $0.88 |
| 52 Week High | $123.16 | $17.25 |
| Indicator | NWPX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 43.96 |
| Support Level | $105.00 | $6.92 |
| Resistance Level | $123.16 | $12.09 |
| Average True Range (ATR) | 3.86 | 1.20 |
| MACD | -0.48 | -0.12 |
| Stochastic Oscillator | 75.00 | 28.34 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products, and operates in two segments, Water Transmission Systems (WTS), operating as the Northwest Pipe Company brand, and Precast Infrastructure and Engineered Systems (Precast), which includes the brands NWPX Geneva and NWPX Park. WTS manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. Precast manufactures stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including reinforced concrete pipe (RCP), manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration units, and other environmental and engineered solutions.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.